NO20045556L - Forbindelse om opphever DNA-skade indusert cellesyklus G2 checkpoint og/eller forsterker anti-cancer aktiviteten ved DNA-skadende behandlinger - Google Patents

Forbindelse om opphever DNA-skade indusert cellesyklus G2 checkpoint og/eller forsterker anti-cancer aktiviteten ved DNA-skadende behandlinger

Info

Publication number
NO20045556L
NO20045556L NO20045556A NO20045556A NO20045556L NO 20045556 L NO20045556 L NO 20045556L NO 20045556 A NO20045556 A NO 20045556A NO 20045556 A NO20045556 A NO 20045556A NO 20045556 L NO20045556 L NO 20045556L
Authority
NO
Norway
Prior art keywords
checkpoint
dna
cell cycle
compound
induced cell
Prior art date
Application number
NO20045556A
Other languages
English (en)
Inventor
Takumi Kawabe
Hidetaka Kobayashi
Original Assignee
Canbas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canbas Co Ltd filed Critical Canbas Co Ltd
Publication of NO20045556L publication Critical patent/NO20045556L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00Thiocarboxylic acids
    • C07C327/20Esters of monothiocarboxylic acids
    • C07C327/26Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to carbon atoms of six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00Thiocarboxylic acids
    • C07C327/36Esters of dithiocarboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/65One oxygen atom attached in position 3 or 5
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Det beskrives preparater og metoder for å inhibere cellesyklus-G2-kontrollpunktet og særlig det DNA-skadeinduserte G2-kontrollpunkt, i pattedyrceller inkludert humanceller. Spesifikt tilveiebringer oppfinnelsen preparater og metoder for å sensitisere celler mot DNA-skadende midler ved å abrogere cellesyklus-G2kontrollpunktet. Forbindelsene benyttes for å behandle proliferative lidelser som cancer. Det tilveiebringes preparater og metoder for selektivt å sensitisere G1-kontrollpunktforringede cancerceller mot DNA-skadende midler og behandlinger.
NO20045556A 2002-06-06 2004-12-20 Forbindelse om opphever DNA-skade indusert cellesyklus G2 checkpoint og/eller forsterker anti-cancer aktiviteten ved DNA-skadende behandlinger NO20045556L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38693002P 2002-06-06 2002-06-06
PCT/IB2003/003164 WO2003104181A2 (en) 2002-06-06 2003-06-06 Compounds that abrogate dna-damage-induced cell cycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments

Publications (1)

Publication Number Publication Date
NO20045556L true NO20045556L (no) 2005-03-04

Family

ID=29736236

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045556A NO20045556L (no) 2002-06-06 2004-12-20 Forbindelse om opphever DNA-skade indusert cellesyklus G2 checkpoint og/eller forsterker anti-cancer aktiviteten ved DNA-skadende behandlinger

Country Status (13)

Country Link
US (4) US7030111B2 (no)
EP (1) EP1511713B8 (no)
JP (2) JP4919598B2 (no)
KR (1) KR100984951B1 (no)
CN (1) CN100577631C (no)
AT (1) ATE520653T1 (no)
AU (1) AU2003247044B8 (no)
CA (1) CA2487388C (no)
ES (1) ES2369534T3 (no)
IL (2) IL165323A0 (no)
NO (1) NO20045556L (no)
WO (1) WO2003104181A2 (no)
ZA (1) ZA200409650B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003247044B8 (en) * 2002-06-06 2009-04-09 Canbas Co. Ltd. Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA-damaging treatments
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
JP2007501608A (ja) * 2003-08-08 2007-02-01 株式会社 キャンバス 抗癌治療の効力を推定するための感受性試験
WO2007097010A1 (ja) * 2006-02-21 2007-08-30 The Kitasato Institute Fki−2342物質およびその製造法
CA2679955A1 (en) * 2006-10-13 2008-05-29 Reliance Life Sciences Pvt. Ltd. Novel chemotherapeutic agents against inflammation and cancer
HUE059861T2 (hu) * 2007-04-11 2023-01-28 Canbas Co Ltd N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
EP3578974A1 (en) * 2018-06-08 2019-12-11 Novagray Bleomycin for mimicking the effect of ionizing radiations on t cells

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2913483A (en) * 1958-05-08 1959-11-17 Dow Chemical Co Lower alkylphenyl 2, 4-dichloro-benzoates
DE2049865A1 (en) 1970-10-10 1972-04-13 Dynamit Nobel Ag, 5210 Troisdorf Aromatic acid aryl esters - prepd from aromatic trichloromethyl cpds phenols and water
US4394389A (en) 1979-03-01 1983-07-19 Riet Bartholomeus Van T Hydroxybenzohydroxamic acids, benzamides and esters as ribonucleotide reductase inhibitors
JPS56110777A (en) * 1980-02-07 1981-09-02 Chisso Corp Ester derivative of 4-fluorobenzoic acid
US4612386A (en) * 1980-09-16 1986-09-16 The Dow Chemical Company Process for making esters
JPS58188838A (ja) * 1982-04-27 1983-11-04 Chisso Corp 4−(4′−フルオロベンゾイルオキシ)フエノ−ルのエステル誘導体
US4934389A (en) * 1988-12-06 1990-06-19 Pettiford William L Dental floss dispenser
FR2649977B1 (fr) 1989-07-18 1991-10-04 Cird Esters bi-aromatiques, leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
JP2696434B2 (ja) * 1991-01-23 1998-01-14 富士写真フイルム株式会社 画像形成方法
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US6017958A (en) * 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
CA2216559A1 (en) 1997-09-25 1999-03-25 Michel Roberge G2 checkpoint inhibitors and assay
EP1070068B2 (en) * 1998-03-13 2007-01-17 The University Of British Columbia Granulatimide derivatives for use in cancer treatment
WO1999048495A1 (en) 1998-03-25 1999-09-30 Biosource Technologies, Inc. Benzoates derivatives for inhibiting angiogenesis
EP1218494B1 (en) 1999-09-22 2005-04-06 Canbas Co., Ltd. Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
KR100863090B1 (ko) * 2002-01-17 2008-10-13 다케다 파머수티컬 컴패니 리미티드 항증식 활성을 지니고/지니거나 핵산 손상제 또는 처리제를 증강시키는 펩티드 및 펩티드모방체
US7202244B2 (en) * 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
AU2003247044B8 (en) * 2002-06-06 2009-04-09 Canbas Co. Ltd. Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA-damaging treatments
US6881573B2 (en) * 2003-09-12 2005-04-19 Allan L. Louderback Augmented solvent/detergent method for inactivating enveloped and non-enveloped viruses

Also Published As

Publication number Publication date
US7030111B2 (en) 2006-04-18
ATE520653T1 (de) 2011-09-15
ZA200409650B (en) 2006-09-27
IL165323A0 (en) 2006-01-15
JP2010168398A (ja) 2010-08-05
CA2487388A1 (en) 2003-12-18
US7407985B2 (en) 2008-08-05
US7629364B2 (en) 2009-12-08
EP1511713A2 (en) 2005-03-09
CA2487388C (en) 2011-05-10
EP1511713B8 (en) 2012-02-08
CN1671644A (zh) 2005-09-21
JP2005528457A (ja) 2005-09-22
AU2003247044B2 (en) 2009-03-26
KR20050019730A (ko) 2005-03-03
US20040198727A1 (en) 2004-10-07
IL165323A (en) 2015-05-31
US7652042B2 (en) 2010-01-26
JP4919598B2 (ja) 2012-04-18
CN100577631C (zh) 2010-01-06
US20080227827A1 (en) 2008-09-18
WO2003104181A2 (en) 2003-12-18
WO2003104181A3 (en) 2004-07-29
US20060122269A1 (en) 2006-06-08
US20080293137A1 (en) 2008-11-27
EP1511713B1 (en) 2011-08-17
AU2003247044B8 (en) 2009-04-09
ES2369534T3 (es) 2011-12-01
KR100984951B1 (ko) 2010-10-01
AU2003247044A1 (en) 2003-12-22

Similar Documents

Publication Publication Date Title
NO20033858D0 (no) Aryl- og heteroarylurea-CHK1-inhibitorer for anvendelse som radiosensitiviseringsmidler og chamosensitiviseringsmidler
CY1110084T1 (el) Χρηση συμπυκνωμενων ετεροκυκλικων ενωσεων ως αναστολεις scce για την θεραπευτικη αγωγη δερματικων ασθενειων
BR112012010762A2 (pt) inibidores de prolil hidroxilalse
MX2009011025A (es) Compuestos con actividad anticancer.
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
NO20081349L (no) Pyrrolopyrimidinderivater som Syk-inhibitorer
NO20061194L (no) Mitotiske kinesininbibitorer
NO20052028L (no) Pyridinderivater som CB2 reseptor modulatorer
ATE406351T1 (de) Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
WO2005030121A3 (en) Compounds, compositions and methods
NO20070067L (no) Pyrrolopyridinderivater
DE10393306D2 (de) Mesenchymale Stammzellen des Haarfollikels und deren Verwendung
NO20054361L (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
PT1218494E (pt) Composicoes e metodos para inibir a paragem do ciclo celular g2 e para sensibilizar celulas perante agentes que danificam o adn
CY1111240T1 (el) Παραγωγα ετεροαρυλουριας χρησιμα για την αναστολη της chk1
WO2006021002A3 (en) Compounds useful for inhibiting chk1
TR200401316T4 (tr) Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler
NO20071805L (no) Alkylidentetrahydronaftalenderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere.
NO20045556L (no) Forbindelse om opphever DNA-skade indusert cellesyklus G2 checkpoint og/eller forsterker anti-cancer aktiviteten ved DNA-skadende behandlinger
DE60135482D1 (de) Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungen
NO20081195L (no) Imidazopyridinderivater som kannabinoidreceptorligander
CY1114825T1 (el) Συνθεσεις και μεθοδοι αγωγης διαταραχων υπερπλασιας κυτταρων